Trending Stock News

Barclays Gives Prothena (PRTA) Lower Rating; Archer Capital Management LP Has Lowered Rayonier Advanced Matls (RYAM) Stake

Prothena Corporation plc (NASDAQ:PRTA) Logo

Archer Capital Management Lp decreased Rayonier Advanced Matls Inc (RYAM) stake by 65.65% reported in 2017Q4 SEC filing. Archer Capital Management Lp sold 1.07 million shares as Rayonier Advanced Matls Inc (RYAM)’s stock rose 5.81%. The Archer Capital Management Lp holds 558,391 shares with $11.42M value, down from 1.63 million last quarter. Rayonier Advanced Matls Inc now has $1.00B valuation. The stock decreased 1.33% or $0.26 during the last trading session, reaching $19.29. About 641,733 shares traded. Rayonier Advanced Materials Inc. (NYSE:RYAM) has risen 69.18% since May 21, 2017 and is uptrending. It has outperformed by 57.63% the S&P500.

In a a report made public on Monday morning, equity analysts at Barclays’s research division lowered Prothena Corp (NASDAQ:PRTA)‘s stock rating from aEqual-Weight to Underweight.

Analysts await Rayonier Advanced Materials Inc. (NYSE:RYAM) to report earnings on August, 1. They expect $0.48 earnings per share, up 336.36% or $0.37 from last year’s $0.11 per share. RYAM’s profit will be $24.91 million for 10.05 P/E if the $0.48 EPS becomes a reality. After $0.38 actual earnings per share reported by Rayonier Advanced Materials Inc. for the previous quarter, Wall Street now forecasts 26.32% EPS growth.

More news for Rayonier Advanced Materials Inc. (NYSE:RYAM) were recently published by: Streetinsider.com, which released: “Marcato Capital’s 13F Shows New Stake in Astec Industries (ASTE), Univar (UNVR), Increase in Rayonier (RYAM …” on May 15, 2018. Seekingalpha.com‘s article titled: “Rayonier Advanced Materials (RYAM) Q1 2018 Results – Earnings Call Transcript” and published on May 09, 2018 is yet another important article.

Among 6 analysts covering Rayonier Advanced Materials Inc (NYSE:RYAM), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Rayonier Advanced Materials Inc had 25 analyst reports since August 21, 2015 according to SRatingsIntel. The stock has “Hold” rating by Vertical Research on Thursday, June 1. Atlantic Securities upgraded Rayonier Advanced Materials Inc. (NYSE:RYAM) on Wednesday, August 10 to “Hold” rating. The company was maintained on Wednesday, February 21 by Bank of America. The stock has “Buy” rating by RBC Capital Markets on Tuesday, May 30. The stock of Rayonier Advanced Materials Inc. (NYSE:RYAM) has “Buy” rating given on Monday, May 29 by Bank of America. The rating was downgraded by Citigroup to “Market Perform” on Friday, August 21. The firm has “Outperform” rating given on Friday, September 4 by RBC Capital Markets. As per Sunday, August 20, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained Rayonier Advanced Materials Inc. (NYSE:RYAM) rating on Monday, September 25. RBC Capital Markets has “Buy” rating and $18.0 target. RBC Capital Markets maintained Rayonier Advanced Materials Inc. (NYSE:RYAM) on Thursday, January 11 with “Buy” rating.

More notable recent Prothena Corporation plc (NASDAQ:PRTA) news were published by: Streetinsider.com which released: “Barclays Downgrades Prothena Corp (PRTA) to Underweight” on May 21, 2018, also Seekingalpha.com with their article: “Prothena: What Now?” published on April 24, 2018, Seekingalpha.com published: “Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target” on April 25, 2018. More interesting news about Prothena Corporation plc (NASDAQ:PRTA) were released by: Prnewswire.com and their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Encourages Investors Who Suffered Losses Exceeding …” published on May 17, 2018 as well as Globenewswire.com‘s news article titled: “Prothena to Report First Quarter 2018 Financial Results on May 8” with publication date: May 01, 2018.

The stock decreased 2.05% or $0.32 during the last trading session, reaching $15.28. About 472,527 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has declined 31.00% since May 21, 2017 and is downtrending. It has underperformed by 42.55% the S&P500.

Investors sentiment decreased to 1.18 in Q4 2017. Its down 0.47, from 1.65 in 2017Q3. It turned negative, as 29 investors sold Prothena Corporation plc shares while 32 reduced holdings. 28 funds opened positions while 44 raised stakes. 31.32 million shares or 0.27% more from 31.24 million shares in 2017Q3 were reported. Ameritas Inv holds 3,249 shares or 0.01% of its portfolio. Rock Springs Capital Mngmt Lp holds 310,000 shares or 0.53% of its portfolio. Spark Investment Llc holds 0.03% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 14,900 shares. Morgan Stanley invested in 0% or 156,519 shares. Massachusetts-based Granite Point Mngmt L P has invested 0.11% in Prothena Corporation plc (NASDAQ:PRTA). 27,485 are held by Fisher Asset Mngmt Limited. 6 were reported by Washington Tru Bancorp. Oak Ridge Invs Ltd reported 0.32% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). Millennium Mgmt Ltd Llc holds 0% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 9,026 shares. Legal General Public Limited Company reported 0% stake. Mufg Americas Hldg Corp has 0% invested in Prothena Corporation plc (NASDAQ:PRTA). Advisory Services Network Ltd Liability Corporation invested 0% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). 1,046 are held by Us Bancorp De. Georgia-based Invesco has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Employees Retirement Systems Of Texas has 0.04% invested in Prothena Corporation plc (NASDAQ:PRTA).

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $608.49 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

Analysts await Prothena Corporation plc (NASDAQ:PRTA) to report earnings on August, 14. They expect $-1.11 EPS, down 141.30% or $0.65 from last year’s $-0.46 per share. After $-1.26 actual EPS reported by Prothena Corporation plc for the previous quarter, Wall Street now forecasts -11.90% EPS growth.

Among 14 analysts covering Prothena Corp (NASDAQ:PRTA), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. Prothena Corp has $100 highest and $12 lowest target. $58.53’s average target is 283.05% above currents $15.28 stock price. Prothena Corp had 42 analyst reports since July 22, 2015 according to SRatingsIntel. Oppenheimer downgraded the shares of PRTA in report on Monday, April 23 to “Hold” rating. The stock has “Outperform” rating by RBC Capital Markets on Thursday, November 19. The rating was maintained by Wedbush on Tuesday, August 4 with “Outperform”. The firm earned “Outperform” rating on Friday, February 19 by Wedbush. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. Cantor Fitzgerald maintained Prothena Corporation plc (NASDAQ:PRTA) on Thursday, February 15 with “Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $80.0 target in Wednesday, November 8 report. Jefferies downgraded Prothena Corporation plc (NASDAQ:PRTA) on Monday, April 23 to “Hold” rating. The rating was downgraded by RBC Capital Markets to “Hold” on Monday, April 23. The stock has “Hold” rating by Barclays Capital on Monday, April 23.

Rayonier Advanced Materials Inc. (NYSE:RYAM) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *